Bio-Thera Conducts Simponi Phase III Trial

Study In Psoriatic Arthritis Patients Begins For BAT2506 Golimumab Biosimilar

 
• By Dave Wallace

China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.

Clinical_Trial_Puzzle
Bio-Thera has kicked off a Phase III study for its golimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products